Notizie e Video - XENCOR INC.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences: Piper Sandler 36th Annual Healthcare Conference Date: Tuesday, December 3, 2024 Presentation Time: 2:00 p.m. ET / 11:00 a.m. PT Location: New York City 7th Annual Evercore HealthCONx Conference Date: Wednesday, December 4, 2024 Presentation...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a review of recent business and clinical highlights. “In the past quarter we continued to advance a clinical portfolio of XmAb drug candidates, enrolling patients across multiple Phase 1 and Phase 2 studies in oncology and...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release second quarter 2023 financial results after the market closes on Thursday, August 3, 2023. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update. The live webcast may be accessed...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced the presentation of results from its Phase 1a single-ascending dose study of XmAb ® 564 in healthy volunteers. XmAb564 is a potency-tuned IL-2-Fc fusion protein, engineered to selectively activate and expand regulatory T cells (Tregs) for the potential treatment of patients with autoimmune...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights. “In the first quarter, we and our partners continued to enroll patients across multiple Phase 1 and Phase 2 clinical studies of XmAb drug candidates in oncology and...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release first quarter 2023 financial results after the market closes on Monday, May 8, 2023. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update. The live webcast will be available under...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente, M.D., to Executive Vice President, Chief Development Officer. Dr. Valente has more than 20 years of experience in late-stage biopharmaceutical product development, and she most recently served as a senior vice president at Genentech, a member of the Roche Group, and as its...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented new preclinical data generated from engineered CD28 bispecific antibodies targeting the solid tumor antigens CEACAM5, ENPP3, mesothelin, STEAP1 and Trop-2. For each molecule, in vitro T cell activation was enhanced in combination with a CD3 T cell engager. The data were presented in a poster titled...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on novel XmAb ® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida. “T cells in the tumor microenvironment require engagement of their...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a review of recent business and clinical highlights. “In 2022, we focused on advancing our internal portfolio of XmAb ® drug candidates, including the ongoing Phase 2 studies for vudalimab in combination with...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2022 after the market closes on Thursday, February 23, 2023. Xencor management will host a conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update. The live webcast will...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will present at the virtual 2023 SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 3:40 p.m. ET / 12:40 p.m. PT. A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website located at...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates. Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor, said: “The plug-and-play nature of Xencor’s XmAb ® Fc domains and our protein engineering expertise have enabled a broad portfolio of bispecific antibody and...

Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates PR Newswire IRVING, Texas and MONROVIA, Calif., Jan. 5, 2023 IRVING, Texas and MONROVIA, Calif. , Jan. 5, 2023 /PRNewswire/ -- Caris Life Sciences ® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on January 11, 2023 at 3:45 p.m. PST. A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website . A...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced additional clinical data from expansion cohorts in its Phase 1 study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with relapsed or refractory non-Hodgkin lymphomas. Data will be presented by Krish Patel, M.D., Director of the Lymphoma Program at Swedish Cancer Institute, in a poster session...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate at two upcoming investor conferences: Jefferies London Healthcare Conference Date: Tuesday, November 15, 2022 Presentation Time: 8:00 a.m. GMT / 12:00 a.m. PST Location: London Piper Sandler 34th Annual Healthcare Conference Date: Tuesday, November 29, 2022 Presentation...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of data from the first patients in the Phase 2 combination study of vudalimab, a selective PD-1 x CTLA-4 XmAb ® bispecific antibody, in patients with metastatic castration-resistant prostate cancer (mCRPC) and data from multiple preclinical-stage XmAb programs at the 37th Annual Meeting of the...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced topline clinical data from its Phase 1a single-dose, healthy volunteer study of XmAb ® 564, in development for patients with autoimmune diseases. XmAb564 is a wholly owned, monovalent interleukin-2 Fc fusion protein (IL-2-Fc), engineered with dramatically lowered potency and heightened binding affinity for the...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a review of recent business and clinical highlights. “Xencor’s XmAb ® technologies and protein engineering capabilities enable us to address challenging areas of biology and to continually grow our portfolio, both internally and...